When Raising NAD⁺ Isn’t Enough: Energy Flow vs Energy Supply

What a new human study reveals about NAD⁺ boosters, mitochondria, and why energy flow matters more than supply

For the past decade, NAD⁺ has become one of the most talked-about molecules in aging, brain health, and metabolic medicine. Low NAD⁺ has been linked to fatigue, neurodegeneration, inflammation, and accelerated aging.

Naturally, the idea followed: restore NAD⁺, restore health.

This logic underlies influential NAD-centric frameworks, including those popularized by Christopher Palmer in metabolic psychiatry and Martin Picard in stress biology and allostasis. Both argue—correctly—that mitochondrial metabolism sits at the center of modern chronic disease.

But a new human study in Nature Metabolism quietly exposes a critical limitation in how NAD⁺ is being conceptualized—and why “boosting NAD⁺” often fails to deliver meaningful clinical recovery.

What the new study actually shows

In this randomized human trial, researchers compared three common NAD⁺ precursors:

• nicotinamide (Nam),

• nicotinamide riboside (NR),

• nicotinamide mononucleotide (NMN).

After two weeks:

• NR and NMN doubled circulating (whole-blood) NAD⁺

• Nicotinamide did not raise baseline NAD⁺, despite causing a short-lived spike after ingestion

At first glance, this looks like a win for NAD⁺ boosters. But the mechanistic findings tell a very different story.

The key insight

NR and NMN do not directly increase cellular NAD⁺.

Instead, they must first be processed by the gut microbiome, converted into nicotinic acid (niacin), and only then used to rebuild NAD⁺ via the Preiss–Handler pathway.

Even more striking:

• In human blood cells outside the body, NR and NMN failed to raise NAD⁺ at all

• Only nicotinic acid reliably increased NAD⁺

In other words, this study is not about “potent NAD⁺ boosters.”

It is about precursor routing, microbial metabolism, and pathway constraints.

Circulating NAD⁺ is not the same as cellular NAD⁺

This distinction is often missed.

The study measured whole-blood NAD⁺, dominated by red blood cells and short-lived immune cells. These are metabolically simple compartments. They do not reflect:

• mitochondrial NAD⁺ inside neurons or muscle,

• nuclear NAD⁺ used for DNA repair,

• or NAD⁺ availability in chronically stressed tissues.

Raising circulating NAD⁺ tells us how the body handles precursors, not whether cells can use NAD⁺ to repair, recover, or shut down stress responses.

Where NAD-centric models help—and where they fall short

Palmer: metabolism over neurotransmitters

Palmer’s work was groundbreaking in reframing mental illness as a metabolic disorder of the brain. Ketogenic and metabolic interventions work precisely because they improve energy flow, not because they simply increase molecules.

But in many interpretations of his model, NAD⁺ becomes a limiting reagent:

low NAD⁺ → dysfunction → add NAD⁺ → recovery.

That logic holds only when mitochondria are uncongested.

Picard: mitochondria as signaling hubs

Picard advanced the field further by showing mitochondria as regulators of stress, immunity, and cellular identity. In this framework, NAD⁺ is central to adaptive signaling via sirtuins and PARPs.

Yet here too, NAD⁺ is often treated as an adaptive lever rather than a flux-dependent currency.

Neither model fully accounts for what happens when:

• NAD⁺ regeneration is impaired,

• NAD⁺ consumption remains chronically high,

• and stress programs never shut off.

The missing variable: mitochondrial congestion

Under chronic stress, aging, toxic exposure, or inflammation:

• Electron transport slows

• NADH cannot be efficiently recycled back to NAD⁺

• ATP availability falls

• Meanwhile, NAD⁺ consumption increases:

  • PARPs respond to DNA damage

  • Sirtuins attempt adaptive remodeling

This creates a paradox:

The cell needs more NAD⁺ precisely when it is least able to regenerate it.

In this state, adding NAD⁺ precursors does not solve the problem.

They are rapidly consumed, misallocated, or wasted.

This is why:

• NAD⁺ levels may rise in blood but not in mitochondria

• signaling continues without resolution

• patients feel “stimulated but not better”

ERM reframes NAD⁺ correctly: currency, not capital

The Exposure-Related Malnutrition (ERM) framework resolves this contradiction.

In ERM:

• NAD⁺ is not a master switch

• It is a currency of energy flow

• Its usefulness depends on:

  • mitochondrial throughput,

  • redox recycling,

  • and the ability to terminate stress responses

If the system is congested:

• NAD⁺ becomes a sink, not a solution

• Supplementation adds substrate to a blocked network

• Recovery requires decongestion first, not more fuel

What this means for future translation

The future of NAD⁺-based therapies will not be about stronger boosters.

It will be about:

• identifying when NAD⁺ support helps vs when it fails,

• restoring mitochondrial throughput before supplementation,

• reducing futile NAD⁺ consumption (by resolving damage, not suppressing symptoms),

• integrating gut, immune, and bioenergetic context.

This new study doesn’t undermine metabolic psychiatry or mitochondrial medicine.

It sharpens them.

The message is not “NAD⁺ doesn’t matter.”

The message is:

NAD⁺ only works when energy can flow.

And flow, not supply, is the real bottleneck.

Take-home message

If you are exhausted, inflamed, or stuck in chronic stress adaptation, you are not broken—you are congested.

Before asking how to boost NAD⁺, we need to ask:

Can your mitochondria actually use it?

That shift—from boosting to restoring flow—is where the next generation of metabolic medicine will emerge.

Christen, S., Redeuil, K., Goulet, L. et al. The differential impact of three different NAD⁺ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab 8, 62–73 (2026). https://doi.org/10.1038/s42255-025-01421-8